The Effect of Fibrinolysis Inhibitors on the Ellagic Acid Activation of Hageman Factor in the Dog

Summary The administration of 10 ml/kg b.w. of a 10−4 M ellagic acid solution to dogs primed with saline (control group) caused a marked shortening of the silicone clotting time and a mild shortening of the glass clotting time whereas no changes in the euglobulin lysis time were noted. The administration of the compound to dogs primed with Trasylol (10,000 K.I.U./kg b.w.) failed to cause any change in the clotting times but caused instead a sharp inhibition of fibrinolysis. The administration of ellagic acid to dogs primed with EACA (0.3 g/kg b.w.) caused a shortening of the silicone and glass clotting times similar to that observed in the control group whereas fibrinolysis was not significantly inhibited. These data indicate that Trasylol inhibits Hageman factor activation by ellagic acid whereas EACA has no effect.

[1]  A. S. Douglas,et al.  Studies on the Anticoagulant Action of Aprotinin (“Trasylol”) , 1970, Thrombosis and Haemostasis.

[2]  A. Girolami,et al.  Ellagic acid induced thromboelastographic changes in the normal individual and in several coagulopathies. , 1969, Haematologica Latina.

[3]  G. Müller‐Berghaus,et al.  Activation of Hageman factor by ellagic acid and the generalized Shwartzman reaction. , 1969, The American journal of pathology.

[4]  R. Sheon,et al.  The Demise of John Hageman , 1968 .

[5]  A. S. Douglas,et al.  In vitro and In vivo Studies with Trasylol, an Anticoagulant and a Fibrinolytic Inhibitor , 1968, British journal of haematology.

[6]  M. Hilden,et al.  Inhibition of thromboplastic activity by Trasylol. In vitro investigations concerning the mechanism of inhibition. , 2009, Scandinavian journal of haematology.

[7]  K. Gautvik,et al.  Kinin formation and kininogen depletion in rats after intravenous injection of ellagic acid. , 1967, British journal of pharmacology and chemotherapy.

[8]  B. Blombäck,et al.  Action of a Proteolytic Enzyme Inhibitor on Blood Coagulation in Vitro , 1967, Thrombosis and Haemostasis.

[9]  A. Girolami The action of ellagic acid on the coagulation mechanism and experimental and clinical bleeding. , 1967, Haematologica Latina.

[10]  A. Girolami,et al.  Hypercoagulable State Induced in Humans by the Intravenous Administration of Purified Ellagic Acid , 1967, Thrombosis and Haemostasis.

[11]  C. J. Amris Inhibition of fibrinolytic and thromboplastic activity by Trasylol. , 2009, Scandinavian journal of haematology.

[12]  P. G. Iatridis,et al.  Effects of Ellagic Acid upon the Human Fibrinolytic System , 1966, Thrombosis and Haemostasis.

[13]  W. Connor,et al.  Myocardial infarction associated with severe factor-XII deficiency. , 1966, Lancet.

[14]  H. Glueck,et al.  Myocardial infarction in a patient with a hageman (factor XII) defect. , 1966, Annals of internal medicine.

[15]  Botti Re Assessment of the hypercoagulable state and ellagic acid. , 1966 .

[16]  A. Girolami,et al.  The effect of ellagic acid on coagulation in vivo. , 1966, Blood.

[17]  O. Ratnoff,et al.  STUDIES ON THE PATHOGENESIS OF THROMBOSIS: AN EXPERIMENTAL "HYPERCOAGULABLE" STATE INDUCED BY THE INTRAVENOUS INJECTION OF ELLAGIC ACID. , 1964, The Journal of laboratory and clinical medicine.

[18]  O. Ratnoff,et al.  ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID. , 1964, The Journal of laboratory and clinical medicine.

[19]  S. G. Iatridis,et al.  Actie Hageman factor: a plasma lysokinase of the human fibrinolytic system. , 1962, The Journal of clinical investigation.

[20]  S. Niewiarowski,et al.  Rôle du Facteur Contact (Facteur Hageman) dans la Fibrinolyse , 1959, Thrombosis and Haemostasis.

[21]  E. Cliffton,et al.  Fibrinolytic and proteolytic activity of a human plasminogen, prepared from fraction III of human plasma. , 1953, Journal of applied physiology.

[22]  Congenital Afihrinogenemia A Case Report with Some Considerations on the Hereditary Transmission of · this Disorder , 2022 .